68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma

NANot yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Pancreatic AdenocarcinomaPET / CTFAPISurgical OncologyMolecular Imaging
Interventions
DIAGNOSTIC_TEST

68Ga-FAPI-46 PET/CT

A single-dose intravenous injection of the radiotracer 68Ga-FAPI-46 will be administered to participants. Approximately 60 minutes after injection, a whole-body PET/CT scan will be performed. The scan is designed to detect areas of high fibroblast activation protein (FAP) expression in and around pancreatic tumors, providing high-resolution images of tumor margins and potential spread. The goal is to evaluate whether this imaging method offers more accurate and useful information than standard imaging (MRI and CT) for preoperative staging and surgical planning.

Trial Locations (1)

1011

Centre Hospitalier Universitaire Vaudois, Lausanne

All Listed Sponsors
lead

Centre Hospitalier Universitaire Vaudois

OTHER

NCT06911021 - 68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma | Biotech Hunter | Biotech Hunter